搜索
Scinai Immunotherapeutics Ltd
SCNI添加自选
0.270USD
-0.001-0.29%
收盘 07/02, 13:00（美东）报价延迟15分钟
956.00K总市值
亏损市盈率 TTM
关键数据
0.274今开
0.279最高
32.29K成交量
亏损市盈率 TTM
--市盈率动
--股息TTM
0.91%换手率
0.272昨收
0.263最低
6.15K成交额
0.20市盈率静
0.16市净率
0.00%股息率 TTM
-66.26%ROA
6.18052周最高
0.57量比
4.80M净利润
3.54M总股本
-3.5600每股收益TTM
2.09Beta
-243.39%ROE
0.40752周最低
6.07%振幅
-228.63%毛利率
956.00K总市值
-6.28回报/风险
6.06%风险率
TradingKey Scinai Immunotherapeutics Ltd股票评分
单位: USD 更新时间: 2026-07-02操作建议
Scinai Immunotherapeutics Ltd当前公司基本面数据相对健康，增长潜力稳定。当前估值合理，在生物技术与医疗研究行业排名243/387位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Scinai Immunotherapeutics Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Scinai Immunotherapeutics Ltd亮点
亮点风险
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
业绩增长期
公司处于发展阶段，最新年度总收入1.31M美元
利润高增长
公司净利润处于行业前列，最新年度总收入1.31M美元
业绩转亏
公司业绩转亏，最新年度亏损美元
估值低估
公司最新PE估值-0.08，处于3年历史低位
机构加仓
最新机构持股179.71K股，环比增加15.87%
活跃度降低
近期活跃度降低，过去20天平均换手率-0.44
分析师目标
根据
0
位分析师
--
评级
--
目标均价
--
涨幅空间
Scinai Immunotherapeutics Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Scinai Immunotherapeutics Ltd简介
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
公司代码SCNI
公司Scinai Immunotherapeutics Ltd
CEOReichman (Amir)
网址https://www.scinai.com/
相关品种
热门品种
常见问题
Scinai Immunotherapeutics Ltd(SCNI)的当前股价是多少？
Scinai Immunotherapeutics Ltd(SCNI)的当前股价是 0.27。
Scinai Immunotherapeutics Ltd的股票代码是什么？
Scinai Immunotherapeutics Ltd的股票代码是SCNI。
Scinai Immunotherapeutics Ltd股票的52周最高点是多少？
Scinai Immunotherapeutics Ltd股票的52周最高点是6.18。
Scinai Immunotherapeutics Ltd股票的52周最低点是多少？
Scinai Immunotherapeutics Ltd股票的52周最低点是0.41。
Scinai Immunotherapeutics Ltd的市值是多少？
Scinai Immunotherapeutics Ltd的市值是956.00K。
Scinai Immunotherapeutics Ltd(SCNI)股票的每股收益（EPS TTM）是多少
Scinai Immunotherapeutics Ltd(SCNI)股票的每股收益（EPS TTM）是-3.56。